Advances in the Prevention of Chemotherapy Induced Nausea and Vomiting
Abstract
Oncology practitioners currently have very effective antiemetic agents in the form of 5-hydroxytryptamine-3 receptor antagonists, neurokinin-1 receptor antagonists, dexamethasone, and olanzapine for use in the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy. The choice of individual agents and the combination of agents should be dictated by the emetogenicity of the chemotherapy and patient risk factors. The available agents for the prevention of CINV appear to be safe and effective with few reported adverse events when used in the recommended doses.The use of these agents in various clinical settings is described by established antiemeticguidelines from the Multinational Association of Supportive Care in Cancer and the European Society of Medical Oncology, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network. Practitioners should follow these guidelines in order to provide the highest possible quality of care for patients receiving chemotherapy.
Keywords
Full Text:
Subscribers OnlyReferences
Bloechl-Daum, B., et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006. 24: 4472-78.
Cohen, L., et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007; 15: 497-503.
Navari, R.M. and M Aapro Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. New Engl J Med. 2016. 374: 1356-67.
Grunberg, S.M., Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment—how are we doing? J Support Oncol, 2004; 2: 1-10.
Broder, M.S., et al. The impact of 5HT3RA use on cost and utilization in patients with chemotherapy-induced nausea and vomiting: systematic review of the literature. Am Health Drug Benefits. 2014; 7: 171-82.
Navari, R.M., Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agents. Drugs. 2013; 73: 249-62.
Navari, R.M., Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014; 15: 2599-2608.
Aapro, M., A. Carides, and B. L. Rapoport, Aprepitant and fosaprepitant: a ten-year review of efficacy and safety. The Oncologist. 2015; 20: 450-58.
Navari, R.M., Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Design, Development and Therapy. 2015; 9: 155-61.
Navari, R.M., Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Therapy. 2015; 15: 1127-33.
Navari, R.M., et al., A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer. 2007; 15: 1285-91.
Tan, L., et al., Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009; 28: 1-7.
Navari, R.,M., Gray S.E., and Kerr A. C., Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011: 9: 188-95.
Navari, R.M., et al., Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. New Engl J Med, 2016, 375: 134-42.
Mukhopadhyay, S.,et al., Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. Support Care Cancer 2017, 25: 145-54.
Molassiotis, A., et al., MASCC/ESMO Antiemetic guidelines: introduction to the 2016 guideline update Support Care Cancer 2017; 25; 267-71.
Hesketh, P.J., et al., Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017; 35: 3240-61.
NCCN Clinical Practice Guidelines in Oncology version 2.2017. Antiemesis. National Comprehensive Cancer Network (NCCN) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. [Accessed June, 2017]
Simpson, K, C.M. Spencer and K.J. McClellan. Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000 59; 1297-1315.
Kimura E., et al., Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho, 1996, 23; 477-81.
Taguchi T., et al., Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho, 1999; 26: 1163-70.
Hesketh P.J., Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest 2000; 18: 163-73.
Roila F., et al., Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 2005; 13: 104-8.
Geling, O. and H. Eichler, Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005; 23: 1289-94.
Hickok, J.T., et al., 5-HT3 receptor antagonists versus perchlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncol 2005; 6: 765-72.
Saito, M., et al., Palonosetron plus dexamethasone versus granisetron plus dexamethasone for the prevention of nausea and vomiting during chemotherapy: a double-blind, double dummy, randomized, comparative phase III trial. Lancet Oncol. 2009; 10: 115-24.
Warr, D.G., et al., Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol, 2005; 23: 2822-30.
Boccia, R.,V., et al., Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011; 19: 1609-17.
Raftopoulos H., et al., Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double blind, noninferiority phase III trial. Support Care Cancer 2015; 23: 723-32.
Eisenberg P., et al., Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol. 2004; 15: 330-7.
Rojas, C., et al., Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. J Pharmacol. 2010; 626: 193-99;
Popovic, M., et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2014; 22: 1485-97.
Yavas, C., et al., Acute effect of palonosetron electrocardiographic parameters in cancer patients; a prospective study. Support Care Cancer. 2012; 20: 2343- 47.
Aogi, K., et al., A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer 2012; 20: 1507-14.
Diemunsch, P. and L Grelot, Potential of substance P antagonists as antiemetics. Drugs. 2000; 60: 533-46.
Sankhala, K.K., et al., Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol. 2009; 12: 1607-14.
Navari, RM., Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007; 16: 1977-85.
Grunberg, S., et al., Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol. 2011; 29: 1495-1501.
Ottoboni, T., et al., Bioequivalence of HTX-019 (aprepitant IV)(Cinvanti) and fosaprepitant in healthy subjects. Hematology/Oncology Pharmacy Association Annual Conference. March 29-April 1, 2017, Anaheim, CA.
Rizzi, A., et al., In vitro and in vivo pharmacological characterization of the novel NK-1 receptor selective antagonist Netupitant. Peptides. 2012; 37: 86-97.
Hesketh, P.J., et al., Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014; 25: 1340-46.
Aapro, M., et al., A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014; 25: 1328-33.
Gralla, R.J., et al., A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol, 2014; 25: 1333-39.
FDA News Release, FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy. Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements. Accessed 9 June 2017.
Duffy, R.A., et al., Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK-1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Biochem Behav. 2012; 102: 95-100
Poma, A., et al., Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrate. SupporCare Cancer. 2013; 21, S154, Abstract 441.
Schwartzberg, L., et al., Safety and efficacy assessment of rolapitant for the prevention of chemotherapy‐induced nausea and vomiting following administration of moderately emetogenic chemotherapy in cancer patients in a randomized phase 3 trial. Lancet Oncol. 2015; 16: 1071-78.
Rapoport, B., et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy‐induced nausea and vomiting following administration of cisplatin-based highly emetogenic chemotherapy in cancer patients in two randomized phase 3 trials. Lancet Oncol. 2015; 16: 1079-89.
Fulton, B. and K.L. Goa, Olanzapine : a review of its pharmacological properties and Therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1999 ; 53 : 281- 98.
Kando, J.C., et al., Olanzapine : a new antipsychotic agent with efficacy in the management of schizophrenia. Ann Pharmacother. 1997 ; 31: 1325-34.
Bymaster, F.P., et al, Radioreceptor binding profile of the atypical antipsychotic olanzapine, Neuropsychopharmacology. 1996; 14: 87–96.
Stephenson, C.M.E. and L.S. Pilowski, Psychopharmacology of olanzapine: a review. Brit J Psychiatry. 1999; 174: 52-58.
Petersen, A.B., et al., Adverse effects associated with high dose therapy in patients admitted to inpatient psychiatric care. Clin Toxicol. 2014; 52: 39-43.
Passik, S., et al., A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Investigation. 2004; 22: 383-88.
Goldstein, L.E., et al., New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999 ; 40: 438-43.
Mizukami, N., et al., Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy : a randomized, double-blind placebo-controlled study. J Pain Symptom Manage. 2014 ; 47: 542-50.
Navari, R.M., C. K. Nagy, and S.E.Gray, Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, Supportive Care Cancer. 2013; 21: 1655-63.
Van Sickle, M.D.,et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 2005, 310: p. 329-32.
Darmani, N.A., Delta-9-tetrahydrocannabinol differentially supresses cisplatin-induced emesis and indices of motor function via cannabinoid CB1 receptors in the least shrew. Pharmacol Biochem Behav. 2001 ; 69: 239-49.
Meiri, E., et al., Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007 ; 23: 533-43.
Davis, M.P., Oral nabilone capsules in the treatment of chemotherapy-induced nausea and Vomiting and pain. Expert Opin Investig Drugs. 2008; 17: 85-95.
May, M.B. and A.E. Grode, Dronabinaol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics. Cancer Manag Res. 2016; 8: 49-55.
Badowski, M.L., A review of oral cannabinoids and medical marijuana for the treatment of CINV : a focus on pharmacokinetic variability and pharmacodynamics. Cancer Chemotherapy Pharmacol. 2017; 80: 441-9.
Navari, R.M., Should behavioral therapy be used as the primary treatment to control anticipatory vomiting? HemeOnc Today. 2016; 17: 13.
Navari, R.M., Cancer patients at high risk for chemotherapy-induced nausea and vomiting - prediction assessments/tools. Expert Rev Quality Cancer Care. 2017; 2: 102-8.
Navari, R.M. Treatment of chemotherapy-induced nausea. Community Oncol. 2012;9:20-6.
Ng, T.L., B. Hutton and M. Clemons Chemotherapy-induced nausea and vomiting: Time for more emphasis on nausea? The Oncologist. 2015; 20: 576-83.
DOI: http://dx.doi.org/10.18103/imr.v4i4.705
Refbacks
- There are currently no refbacks.